Logo Logo
Switch Language to German

Altenburg, Arwen F.; Sandt, Carolien E. van de; Li, Bobby W. S.; MacLoughlin, Ronan J.; Fouchier, Ron A. M.; Amerongen, Geert van; Volz, Asisa; Hendriks, Rudi W.; Swart, Rik L. de; Sutter, Gerd ORCID logoORCID: https://orcid.org/0000-0001-6143-082X; Rimmelzwaan, Guus F. and Vries, Rory D. de (2017): Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. In: Scientific Reports, Vol. 7, 8580 [PDF, 8MB]


Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vitro, ex vivo and in vivo experiments with recombinant MVA expressing green fluorescent protein (rMVA-GFP). In both human peripheral blood mononuclear cells and mouse lung explants, rMVA-GFP predominantly infected antigen presenting cells. Subsequent in vivo experiments performed in mice, ferrets and non-human primates indicated that preferential targeting of dendritic cells and alveolar macrophages was observed after respiratory administration, although subtle differences were observed between the respective animal species. Following intramuscular injection, rMVA-GFP was detected in interdigitating cells between myocytes, but also in myocytes themselves. These data are important in advancing our understanding of the basis for the immunogenicity of MVA-based vaccines and aid rational vaccine design and delivery strategies.

Actions (login required)

View Item View Item